

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10571882
	Filing Date		2006-12-12
	First Named Inventor	Barnett	
	Art Unit	1648	
	Examiner Name	Humphrey	
	Attorney Docket Number	032441.00141	

### U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5840313		1998-11-24	Vahlne et al	
	2	5846546		1998-12-08	Hurwitz et al	
	3	5876731		1999-03-02	Sia et al	
	4	6602705		2003-08-05	Barnett et al	
	5	6689879		2004-02-10	Barnett et al	
	6	7211659		2007-05-01	Zur Megede et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

### U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
-------------------	---------	--------------------	------------------------	------------------	---	--

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10571882
Filing Date		2006-12-12
First Named Inventor	Barnett	
Art Unit	1648	
Examiner Name	Humphrey	
Attorney Docket Number	032441.00141	

	1					
--	---	--	--	--	--	--

If you wish to add additional U.S. Published Application citation information please click the Add button.

**FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	03020876	WO		2003-03-13	Chiron Corp.		<input type="checkbox"/>
	2	03038057	WO		2003-05-08	Genphar, Inc.		<input type="checkbox"/>
	3	03077859	WO		2003-09-25	Merck & Co, Inc.		<input type="checkbox"/>
	4	0203917	WO		2002-01-17	Alphavax Inc; University of North Carolina		<input type="checkbox"/>
	5	0181609	WO		2001-11-01	Chiron Corp.		<input type="checkbox"/>
	6	0376598	WO		2003-09-18	Merck & Co, Inc.		<input type="checkbox"/>
	7	9834640	WO		1998-08-13	Merck & Co, Inc.		<input type="checkbox"/>
	8	0039302	WO		2000-07-06	Chiron Corp.		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10571882
Filing Date	2006-12-12
First Named Inventor	Barnett
Art Unit	1648
Examiner Name	Humphrey
Attorney Docket Number	032441.00141

9	0039303	WO		2000-07-06	Chiron Corp.		<input type="checkbox"/>
10	0039304	WO		2000-07-06	Chiron Corp.		<input type="checkbox"/>
11	0204493	WO		2002-01-17	Chiron Corp.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	Amara et al., "Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine," J Virol. 2002 Jun;76(12):6138-46.	<input type="checkbox"/>
	2	André et al., "Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage," J Virol. 1998 Feb;72(2):1497-503.	<input type="checkbox"/>
	3	Barnett et al., "The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region," J Virol. 2001 Jun;75(12):5526-40.	<input type="checkbox"/>
	4	Buge et al., "An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge," J Virol. 1997 Nov;71(11):8531-41.	<input type="checkbox"/>
	5	Chakrabarti et al., "Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization," J Virol. 2002 Jun;76(11):5357-68.	<input type="checkbox"/>
	6	Yang et al., "Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibrin," J Virol. 2002 May;76(9):4634-42.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10571882
Filing Date	2006-12-12
First Named Inventor	Barnett
Art Unit	1648
Examiner Name	Humphrey
Attorney Docket Number	032441.00141

7	Yang et al., "Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers," J Virol. 2001 Feb;75(3):1165-71.	<input type="checkbox"/>
8	zur Megede et al., "Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines," J Virol. 2003 Jun;77(11):6197-207.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.